What are thrombosis risk and management considerations in COVID-19?

Authors

Geoffrey D. Barnes
Adam Cuker
Tyler J Gluckman, Providence Heart and Vascular Institute, Portland, OR, USA.Follow
Gregory Piazza
Deborah M. Siegal

Document Type

Article

Publication Date

4-22-2020

Publication Title

ACC Feature | Key Questions on COVID-19 and Cardiovascular Disease

Keywords

cards; cards publication; 2019-nCoV

Abstract

Principal Guidance: The apparent increased thrombotic risk in COVID-19 patients is sufficient to recommend pharmacological VTE prophylaxis in all hospitalized patients unless contraindicated; D-dimer levels may be valuable for clinical monitoring, but there is currently no evidence supporting its use to guide anticoagulation intensity beyond clinical judgment; post-discharge VTE prophylaxis with a DOAC should be considered.

Clinical Institute

Cardiovascular (Heart)

Department

Cardiology

Department

Infectious Diseases

Recommended Citation

Barnes, Geoffrey D.; Cuker, Adam; Gluckman, Tyler J; Piazza, Gregory; and Siegal, Deborah M., "What are thrombosis risk and management considerations in COVID-19?" (2020). Articles, Abstracts, and Reports. 4117.
https://digitalcommons.providence.org/publications/4117